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Abstract: Human mesenchymal stromal/stem cells (hMSCs) show great promise in cell therapy due to
their immunomodulatory properties. The overall immunomodulatory response of hMSCs resembles the
resolution of inflammation, in which lipid mediators and regulatory macrophages (Mregs) play key roles.
We investigated the effect of hMSC cell-cell contact and secretome on macrophages polarized and activated
toward Mreg phenotype. Moreover, we studied the effect of supplemented polyunsaturated fatty acids
(PUFAs): docosahexaenoic acid (DHA) and arachidonic acid, the precursors of lipid mediators, on hMSC
immunomodulation. Our results show that unlike hMSC cell-cell contact, the hMSC secretome markedly
increased the CD206 expression in both Mreg-polarized and Mreg-activated macrophages. Moreover,
the secretome enhanced the expression of programmed death-ligand 1 on Mreg-polarized macrophages
and Mer receptor tyrosine kinase on Mreg-activated macrophages. Remarkably, these changes were
translated into improved Candida albicans phagocytosis activity of macrophages. Taken together,
these results demonstrate that the hMSC secretome promotes the immunoregulatory and proresolving
phenotype of Mregs. Intriguingly, DHA supplementation to hMSCs resulted in a more potentiated
immunomodulation with increased CD163 expression and decreased gene expression of matrix
metalloproteinase 2 in Mreg-polarized macrophages. These findings highlight the potential of PUFA
supplementations as an easy and safe method to improve the hMSC therapeutic potential.
Keywords: cell therapy; immunomodulation; polyunsaturated fatty acid; CD206; phagocytosis
1. Introduction
Mesenchymal stromal/stem cells (MSCs) show great promise in cell therapy, such as in the treatment
of graft-versus-host disease [1,2] and Crohn’s disease [3,4]. MSCs have diverse immunomodulatory
effects, which are mediated via cell-cell contact and secreted paracrine factors, such as extracellular
vesicles (EVs), tryptophan-degrading enzyme indoleamine-2,3-dioxygenase and lipid mediator
prostaglandin E2 (PGE2) [5–7]. MSCs are able to, e.g., inhibit the proliferation of T cells and promote
the generation of regulatory T cells [5,8]. Moreover, MSCs polarize macrophages toward a more
anti-inflammatory phenotype by increasing the expression of multiple cell surface markers, such as
CD206, and by enhancing their phagocytosis activity [9–12].
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A tight classification of macrophages into different subtypes is redundant due to their plastic
and rapidly changing phenotype giving rise to a heterogeneous population [13]. Yet for simplicity,
macrophages are typically classified into classically activated, proinflammatory M1 phenotype and
to wound healing, anti-inflammatory M2 phenotype. Regulatory macrophages (Mregs) represent an
immunoregulatory phenotype that produce anti-inflammatory cytokines, such as interleukin (IL)-10
and transforming growth factor β1 (TGF-β1), potently suppress T-cell function and promote regulatory
T-cell phenotype [14,15]. Interestingly, Mregs are also investigated as a potential adjunct therapy in
renal transplantations (clinicaltrials.gov: NCT02085629). Although the effects of MSCs on monocytes
and type M1 and M2 macrophages have been intensively studied, less is known about the effects
of MSCs on Mregs. In our previous study, we observed that human bone marrow-derived MSCs
(hBMSCs) and hBMSC-derived EVs (hBMSC-EVs) enhanced the anti-inflammatory phenotype of
Mregs [16]. Both hBMSC cell-cell contact and EVs decreased the production of IL-23 and IL-22,
which are up-regulated in inflammation and promote T helper 17 cell maintenance and proliferation,
respectively. The hBMSCs and EVs also increased the production of PGE2 [16], which is an essential
lipid mediator in MSC function and induces the MSC-mediated skewing of macrophages toward an
anti-inflammatory phenotype [11,17].
EVs are small (majority < 300 nm) lipid-bilayered particles secreted by cells through exocytosis
and membrane budding. EVs carry intracellular messages by transporting lipids, proteins, nucleic
acids, carbohydrates or their metabolites and can mediate immunological effects [18]. Intriguingly,
MSC-EVs are able to mediate the therapeutic response of MSCs and have been investigated in various
in vivo models, such as acute kidney injury [19], stroke [20,21] and sepsis [22]. Thus, MSC-EVs have
emerged as a cell-free therapeutic option for MSCs.
The immunomodulatory response of MSCs resembles the resolution of inflammation, the active
dampening phase of inflammation [23]. Lipid mediators, especially the specialized proresolving mediators
(SPMs) promote the resolution of inflammation [24] by, e.g., reducing neutrophil trafficking, increasing
macrophage polarization toward anti-inflammatory phenotype and macrophage efferocytosis of
apoptotic neutrophils. Polyunsaturated fatty acids (PUFAs), such as n-3 docosahexaenoic acid (DHA),
eicosapentaenoic acid (EPA) and n-6 arachidonic acid (AA) are precursors to lipid mediators [25].
DHA is a precursor to resolution-phase SPMs such as D-series resolvins, maresins and protectins and
EPA to E-series resolvins. AA is a precursor to proresolving lipoxins, but also for prostaglandins (PGs),
thromboxanes and leukotrienes with mainly proinflammatory functions.
We have previously demonstrated that the phospholipid, fatty acid and, importantly, lipid mediator
profiles of hBMSCs can be modified with the supplementation of PUFAs [26,27]. hBMSCs cannot
efficiently synthetize these long-chained PUFAs from n-6 and n-3 precursors rendering the PUFA
supplementation into the culture medium essential to ensure a sufficient level of precursors for lipid
mediator biosynthesis [26]. Interestingly, we also observed that PUFA supplementation to hBMSCs
caused the subsequent remodeling of the phospholipid membrane of hBMSC-EVs [27]. Furthermore,
EPA and DHA supplementation to murine MSCs increases their immunomodulatory capacity in
allergic asthma [28] and sepsis [29,30] models, highlighting the importance of PUFA modifications on
MSC immunomodulation.
In this study, we investigated the effect of hBMSC cell-cell contact and secretome on polarized
and activated Mregs. Moreover, we investigated the immunomodulatory effect of hBMSCs on
Mregs after DHA or AA supplementations, which alter the downstream lipid mediator profile of
hBMSCs. Our results demonstrate that the hBMSC secretome skewed macrophages toward a more
anti-inflammatory and proresolving phenotype. This effect was even more pronounced by the secretome
of DHA-modified hBMSCs. Strikingly, we show for the first time that the hBMSC secretome enhanced
the Candida albicans phagocytosis activity of macrophages by increasing the CD206 expression.
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2. Materials and Methods
2.1. hBMSC Culture and PUFA Supplementation
The patient protocols of the hBMSC isolation were approved by the Ethical Committee of Northern
Ostrobothnia Hospital District (ethical approval number: Oulu University hospital EETTMK 21/2011).
The hBMSCs were collected from upper femur metaphysis of adult patients after receiving a written
informed consent and characterized as described previously [31]. The cells have been characterized
according to the guidelines of the International Society of Cell & Gene Therapy [32]. The cells
expressed typical MSC markers and lacked the expression of hematopoietic stem cell markers, and the
differentiation toward osteoblasts and adipocytes was also tested (data not shown). hBMSCs derived
from three donors were inspected in this study.
The cells were thawed, cultured [27] and PUFAs supplemented [26] as described previously.
In brief, the hBMSCs at confluence of 80–90% were supplemented with ethanol (purity ≥99.5%,
Altia Industrial, Rajamäki, Finland) as a control, DHA or AA (Cayman Chemical, Ann Arbor, MI,
USA) as bovine serum albumin (BSA, Merck, Darmstadt, Germany) conjugates. Prior to the PUFA
supplementation, the medium was changed to medium containing only 5% fetal bovine serum (FBS,
Thermo Fisher Scientific, Waltham, MA, USA) in contrast to 10% FBS in the proliferation medium.
The PUFAs dissolved in ethanol were added into 1.5 mM BSA-Dulbecco’s phosphate buffered saline
(DPBS, Thermo Fisher Scientific) solution, vortexed and immediately added to the cell culture medium.
The final PUFA concentration supplemented to the cells was 50 µM. After 24 h, hBMSCs were detached
and 50,000 cells/well were added into Mreg polarization assay.
2.2. Mreg Polarization Assay
The use of anonymized peripheral blood mononuclear cells (PBMCs) from blood donors in
research is in accordance with the rules of the Finnish Supervisory Authority for Welfare and Health
(Valvira, Helsinki, Finland). The layout of the assay is described in Figure 1 and macrophages derived
from six different donors were used in the assay. The Mregs were cultured as described in [16] with
certain changes. In brief, 2 × 106–4 × 106 PBMCs were plated on 12-well plates (Corning™ Costar™ flat
bottom, Thermo Fisher Scientific), incubated for 1–2 h and washed with DPBS. The attached monocytes
were incubated in 1.5 mL RPMI-1640 medium (Thermo Fisher Scientific) with 10% FBS (Merck),
GlutaMAX™ supplement (Thermo Fisher Scientific) and 5 ng/mL macrophage colony-stimulating
factor (M-CSF, PromoCell, Heidelberg, Germany) for 6 days at 37 ◦C, 5% CO2. This medium is referred
as polarization medium and macrophages obtained in these conditions are referred as Mreg-polarized
macrophages from here onwards. At day 6, the medium was changed into the polarization or activation
medium [polarization medium with 25 ng/mL interferon (IFN)-γ and 10 ng/mL lipopolysaccharide (LPS,
both from Merck)]. Macrophages cultured in the activation medium are referred as Mreg-activated
macrophages. The next day, 50,000 control-hBMSCs, DHA-hBMSCs or AA-hBMSCs were added to the
bottom of wells (referred as hBMSC cell-cell contact) or to inserts (Corning™ Transwell™, pore size
0.4 µm, Thermo Fisher Scientific) (referred as the hBMSC secretome).
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Figure 1. The layout of macrophage polarization assay. Mreg, regulatory macrophage; hBMSC, human bone
marrow-derived mesenchymal stromal cell; DHA, docosahexaenoic acid; AA, arachidonic acid; M-CSF,
macrophage colony-stimulating factor; IFN, interferon; LPS, lipopolysaccharide.
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At day 10, the medium was centrifuged at 300× g for 15 min and the supernatant was snap frozen
and stored at −80 ◦C. The cells were washed with DPBS and either detached for flow cytometry with
0.75 µL 4 ◦C Macrophage Detachment Solution DFX (PromoCell) or scraped into 600 µL RLT lysis
buffer (Qiagen, Hilden, Germany) for quantitative polymerase chain reaction (QPCR). The RLT samples
were snap frozen and stored at −80 ◦C.
2.3. Determination of Cytokine Production
The medium samples were thawed on ice and analyzed with human tumor necrosis factor
(TNF)-α, IL-10 and IL-23 DuoSet enzyme-linked immunosorbent assays (ELISA) (all from R&D
Systems, Minneapolis, MN, USA) according to the manufacturer’s protocol. The absorbance was
measured with CLARIOstar® microplate reader (BMG Labtech, Ortenberg, Germany).
2.4. Macrophage Phenotyping with Real-Time Quantitative PCR
Only the macrophages with hBMSC secretome samples (hBMSCs cultured on an insert) were analyzed
with real-time QPCR, because cell-cell contact samples included both macrophages and hBMSCs. The RNA
was extracted using RNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol. The concentration
and purity of RNA was measured with NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific).
RNA was converted to complementary DNA with High Capacity cDNA RT Kit (Thermo Fisher
Scientific). The gene expression was analyzed with real-time QPCR (CFX96™ Real-Time Systems and
C1000™ Thermal Cycler, Bio-Rad, Hercules, CA, USA) using TaqMan® Gene Expression assays and
TaqMan® Universal Master Mix II (Thermo Fisher Scientific). The following genes were analyzed:
TGFB1 (ID: Hs00998133_m1), MMP2 (ID: Hs01548727_m1), DHRS9 (ID: Hs00608375_m1), STAT3 (ID:
Hs00374280_m1) and STAT1 (ID: Hs01013996_m1). HPRT1 was used as the reference gene. Samples
were analyzed as duplicates and the results were analyzed with CFX Manager™ 3.0 (Bio-Rad) and
with the 2−∆∆Ct method using HPRT1 as the reference gene [33]. The relative gene expression levels are
expressed as log2 fold change relative to the Mreg-polarized or Mreg-activated macrophages cultured
without hBMSCs.
2.5. Macrophage Phenotyping with Flow Cytometry
The antibody staining was performed as described in Hyvärinen et al. (2018) using anti-human
antibodies PE-CF594-CD86 (clone 2331 FUN-1), APC-CD206 (clone 19.2), BV421-CD163 (clone GHI/61),
PerCP-Cy™5.5-CD90 (clone 5E10) (from BD Biosciences, San Diego, CA, USA), FITC-HLA-DR
(clone L243), BV 510™-CD274 (PD-L1, B7-H1, clone 29E.2A3), PE/Cy7-CD120b (TNFR2, clone 3G7A02)
(from BioLegend, San Diego, CA, USA) and PE-MERTK (clone HMER5DS, Thermo Fisher Scientific).
Cell viability was determined with LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit (Thermo
Fisher Scientific). Data was acquired with BD FACSAria IIU (BD Biosciences) flow cytometer using
FACSDiva™ (v8.0.1, BD Biosciences) and analyzed with FlowJo® (v10, BD Biosciences). Gating strategy
and doublet discrimination is depicted in Figure S1. Fluorescence positive cells were determined by
using isotype controls and CD90 positive cells were excluded from the analysis (Figure S1). The results
are presented as median fluorescence intensity (MFI) and frequency of positive cells and as their
log2 fold change values relative to the Mreg-polarized or Mreg-activated macrophages cultured
without hBMSCs.
2.6. Yeast Heat-Inactivation and CFSE-Staining
Lyophilized C. albicans pellets (ATCC® 10231™, Microbiologics, Saint Cloud, MN, USA) were dissolved
in 1 mL NaCl Peptone Broth solution (Merck) for 30 min at 37 ◦C according to the manufacturer’s protocol.
The yeast solution was incubated for 1 h in 80 ◦C to kill the cells [34]. Yeast solution (1 × 107 cells/mL) was
stained with 2 µM carboxyfluorescein succinimidyl ester (CFSE, Thermo Fisher Scientific) for 15 min
at 37 ◦C. The stained yeast cells were washed with RPMI 1640 and centrifuged at 1000× g for 5 min.
The pellet was suspended with polarization medium at concentration of 5 × 106 cells/mL and filtered.
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The CFSE-stained C. albicans were stored o/n at 4 ◦C. The staining was verified with imaging flow
cytometry (Amnis® ImageStream®X Mark II, Luminex Corporation, Austin, TX, USA). The viability
of heat-killed yeast was tested by the absence of growth on agar plates after 48 h incubation at 37 ◦C.
2.7. Phagocytosis Assay with Imaging Flow Cytometry
Polarized macrophages were cultured with control-hBMSCs on inserts as described above.
Macrophages derived from five different donors were employed in the phagocytosis assay. On day
10, the hBMSC inserts were removed and the medium was replaced with 1 mL polarization medium
containing heat-killed CFSE-stained C. albicans at low (5 × 105 cells/well) or high (1.25 × 106 cells/well)
concentration. The plates were centrifuged at 30× g for 1 min to synchronize the phagocytosis in all
wells and incubated for 45 min at 37 ◦C, 5% CO2. The cells were washed with DPBS, detached, stained
with PE-CF594-CD86 and APC-CD206 and analyzed with imaging flow cytometry.
Amnis® ImageStream®X Mark II 12-channel imaging flow cytometer with the software INSPIRE®
(Luminex Corporation) was used for data collection and analysis. Acquisition settings were as follows:
Excitation lasers 405 (off), 488 (15 mW), 642 (150 mW) and 785 (6.75 mW) were applied for the excitation
of fluorochromes and laser Channels (Ch) 01 and Ch09 (bright field, BF), Ch06 (scattering channel,
SSC), plus fluorescence channels Ch02, Ch04 and Ch11 were activated for signal detection.
All acquisition settings were the same in all experiments. Single cells were separated from debris
and aggregates in the BF channel using the IDEAS features aspect ratio and area. Samples were
acquired at 60×magnification with low flow rate/high sensitivity. At least 2000 events of gated single
cells for each sample were collected. Single color controls were used to create a compensation matrix.
Unlabeled cells and isotype control samples were used to determine the auto fluorescence and the
non-specific background.
Compensated data files were analyzed using algorithms available in the IDEAS® analysis software
(v6.2.188.0). Positive events were gated based on cell morphology and the intensity values of each
fluorescence channel and cell BF images (Figure S2). Gating and compensation values were used as
analysis template for all experimental files. This batch processing of all files assured the comparisons
of each experiment with the other.
2.8. Statistical Analysis
Non-parametric tests were performed due to the non-normal distribution of parameters.
The results are expressed as medians with interquartile ranges (IQR). Pairwise statistical testing was
conducted with Wilcoxon signed rank test. Groupwise statistical testing was conducted with Kruskal-
Wallis rank sum test and post hoc pairwise comparisons using Dunn’s test for multiple comparisons
with Mreg-polarized or Mreg-activated macrophages cultured without hBMSCs. All statistical tests
were conducted with R version 3.5.1 and the PMCMR package [35,36] and p-value < 0.05 was
considered significant.
3. Results
3.1. Phenotype of Polarized and Activated Macrophages
The phenotypes of macrophages were determined by flow cytometry using markers for T-cell
activation costimulatory molecule CD86, major histocompatibility complex class II cell surface receptor
human leukocyte antigen (HLA)-DR, mannose receptor CD206, scavenger receptor CD163, programmed
death-ligand 1 (PD-L1, also known as CD274), tumor necrosis factor receptor 2 (TNFR2) and Mer
receptor tyrosine kinase (MerTK) (Tables S1 and S2). hBMSCs were excluded using CD90 labeling
and were detectable only in the samples with hBMSC cell-cell contact (Figure S1). The median
frequency of dead cells of Mreg-polarized macrophages was 1.6% (IQR 2.5) and 1.9% (IQR 5.4) for
Mreg-activated macrophages.
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The phenotype of Mreg-polarized macrophages is shown in Tables S1 and S2. We observed
considerable donor-specific variation in response to Mreg polarization conditions and subsequently
in the expression of phenotype markers between different buffy coat donors. Approximately, 78% of
these macrophages were positive for CD86, 99.7% for HLA-DR, 35% for CD206, 6% for CD163, 59% for
PD-L1 and <1% for both TNFR2 and MerTK. The phenotype of Mreg-activated macrophages (mature
Mregs) was similar to that of Mreg-polarized macrophages (Tables S1 and S2). Approximately 97% of
the activated macrophages were positive for CD86, 99.9% for HLA-DR, 23% for CD206, <1% for CD163,
92% for PD-L1, negative for TNFR2 and <1% for MerTK. In general, the expression levels of phenotype
markers were similar between the two macrophage types, but the Mreg-activated macrophages had a
higher frequency of CD86+ (pairwise Wilcoxon signed rank test, p = 0.031) and PD-L1+ cells (p = 0.031)
than Mreg-polarized macrophages.
Both macrophage types produced TNF-α and IL-10 (Table 1). The production of TNF-α increased
in Mreg-activated macrophages compared with Mreg-polarized macrophages (pairwise Wilcoxon
signed rank test, p = 0.031) while the production of IL-10 remained at similar levels. The production of
IL-23 was negligible. The donor-specific variation was high in the cytokine production.
Both Mreg-polarized and Mreg-activated macrophages expressed TGF-β1, matrix metalloproteinase
(MMP)-2, human Mreg marker dehydrogenase/reductase 9 (DHRS9) [15], signal transducer and
activator of transcription (STAT)3 and STAT1, determined with QPCR. There were no statistically
significant differences in gene expression between the two macrophage types (not shown). Expression
was, again, variable depending on the donor.
3.2. hBMSC Secretome Skews Mreg-Polarized and Mreg-Activated Macrophages toward an Anti-Inflammatory
and Proresolving Phenotype
The phenotype of both Mreg-polarized and Mreg-activated macrophages was modified especially
by the hBMSCs secretome. The effect of hBMSC cell-cell contact and secretome on the cell surface
protein expression of Mreg-polarized macrophages is shown in Figure 2 and Tables S1 and S2. Strikingly,
the hBMSC secretome increased the log2 fold change of both CD206 MFI (Kruskal-Wallis test with all
hBMSC conditions, p < 0.001; post hoc test p-values are described in Figure 2) and frequency of CD206+
cells (p = 0.002) regardless of the PUFA supplementation. The secretome of control- and DHA-hBMSCs
elevated also the log2 fold change of PD-L1 MFI (p < 0.001) and DHA-hBMSCs the log2 fold change of
CD163 MFI (p = 0.039), but the effect was donor-dependent. Interestingly, hBMSC cell-cell contact with
all PUFA modifications decreased the log2 fold change of HLA-DR MFI (p = 0.001).
The effect of hBMSC cell-cell contact and secretome on the cell surface protein expression of
Mreg-activated macrophages is shown in Figure 3 and Tables S1 and S2. Similar to Mreg-polarized
macrophages, the log2 fold change of CD206 MFI and the frequency of CD206+ cells increased in the
Mreg-activated macrophages by the secretome of hBMSCs with all PUFA modifications (Kruskal-Wallis
test of all hBMSC conditions p < 0.001; post hoc test p-values are described in Figure 3) and with AA
supplementation (p < 0.001), respectively. Moreover, the secretome elevated the log2 fold change
frequency of MerTK+ cells regardless of the PUFA supplementation (p = 0.014). The expression was
still low (<15% positive cells) and the increase was variable between donors. The cell-cell contact had
an effect on only the log2 fold change frequency of HLA-DR+ cells, which was slightly decreased
regardless of the PUFA modification (p < 0.001). The most drastic change in both Mreg-polarized
and Mreg-activated macrophages was the elevated CD206 expression, which is depicted in Figure 4
(presenting the CD206 data in more detail without the log2 fold change values).
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post hoc using Dunn’s test. The results are expressed as log2 fold changes as medians with interquar ile ranges; = 6 biological replicat s. Ctrl, control; DHA,
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Neverthele s, DHA-hBMSCs resulted in a decrease MMP-2 gene expression in the Mreg-polarized
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similar trend. There was also a rend of increased gene expre sion of the Mreg marker DHRS9 in DHA
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3.3. Phagocytosis Assay
The C. albicans phagocytosis activity of Mreg-polarized macrophages was assessed with/without
hBMSCs secretome and the results analyzed with imaging flow cytometry (Figure 6). The macrophages
elicited a donor-dependent CD86 and CD206 expression. In contrast to the previous results, hBMSC
secretome did not increase the CD206 expression in all of the macrophages derived from different
PBMC donors (non-responders n = 2, Figure S3). However, in three cases, the CD206 increased by 1.9
to 4.2 fold when compared with the non-responders, which elicited a 0.7 to 0.8-fold decrease in the
CD206 expression. The results of the CD206 responders are reported in Figure 6. In the responders,
the phagocytosis of low concentration (5 × 105 cells/well) C. albicans increased by 1.6 to 5.8 fold in
the hBMSC secretome group when compared with Mreg-polarized macrophages alone. In general,
the levels of ingested C. albicans were higher in the high concentration (1.25 × 106 cells/well) group and
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regs ( reg-activated macrophages) [37] in order to elucidate the eff ct of hBMSCs on
macrophages at different polariz tion stages. The p notypes of these two macrophage typ s were
similar, but the Mreg-activated macrophages manifested a more classi lly activ ted phenotype with
increased expression of CD86 and PD-L1. Moreover, th Mreg-activ ted macrophages produced more
TNF-α than Mreg-polarized macrophages as expected due to Toll-like receptor engagement by LPS.
Previously, we demonstrated that hBMSC cell-cell contact and hBMSC-EVs enhanced the
anti-inflammatory properties of mature Mregs by decreasing the production of IL-23 and IL-22
and increasing the PGE2 production [16]. In the current study, we did not detect a decrease in
the IL-23 production, which was very low when measured with ELISA (previously analyzed with
ProcartaPlex Immunoassay), but we observed other anti-inflammatory effects of hBMSCs on these
immunoregulatory macrophages. Additionally, the experimental setup and the markers investigated
of these two studies were slightly different.
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The hBMSC secretome enhanced the anti-inflammatory properties of both Mreg-polarized and
Mreg-activated macrophages especially by increasing the CD206 expression. CD206, also known as
mannose receptor, is a pattern recognition receptor, which binds to the glycan structures on microbes [38].
Previous studies have shown that human MSC cell-cell contact or secretome can increase the expression
of CD206 and overall anti-inflammatory properties of monocytes or M1 macrophages [9,11]. Moreover,
human MSC-derived EVs can increase the CD206 and anti-inflammatory properties of murine
macrophages [39]. The secretome consists of secreted cytokines, lipid mediators and other molecules
and also includes EVs. Thus, our results with macrophages polarized toward Mregs are in agreement
with previous studies investigating monocytes or other macrophage subtypes and CD206 expression.
In our preceding study with Mregs, we did not observe an increase in the CD206 expression with
hBMSC-EV addition [16]; however, the experimental settings of our two studies are not directly
comparable. Previously, the EVs added to Mregs were derived from unstimulated hBMSCs and given
in two doses. In the current study, the hBMSCs produced the EVs and additional soluble factors
constantly in a stimulated environment with macrophage coculture.
Next, we investigated if the increased CD206 expression translated to an increased phagocytosis
activity of yeast C. albicans by Mreg-polarized macrophages in the presence of hBMSC secretome.
The cell surface of C. albicans is covered in terminal mannose residues that are recognized by CD206 of
macrophages [38,40]. Interestingly, when the hBMSC secretome increased the CD206 expression in the
responder macrophages, the phagocytosis of C. albicans was also increased indicating an association
between these two hBMSC secretome-mediated phenomena. The effect was PBMC donor-dependent,
because the donors responded to the polarization and hBMSC secretome differently. Both human and
murine MSCs have been shown to induce the phagocytosis of macrophages in various assays [10,12,41]
but to our knowledge this is the first study showing that MSCs induce the phagocytosis of C. albicans.
One of the key aspects in the resolution of inflammation is the clearance of pathogens and apoptotic
cells via phagocytosis and efferocytosis [24]. Phagocytosing macrophages become more prevalent
during resolution of inflammation when the cell debris and microbes are cleared away in order to
achieve homeostasis [24] emphasizing the ability of hBMSC secretome to promote the proresolving
phenotype of macrophages.
In addition to CD206, the PD-L1 expression increased by the hBMSC secretome in Mreg-polarized
macrophages. When PD-L1 binds to its receptor, a co-inhibitory receptor programmed death 1 (PD-1),
T-cell activation and proliferation are inhibited and the immune response is attenuated [42]. PD-L1 is
expressed on the surface of proresolving macrophages [43], which indicates that the hBMSC secretome
skews the macrophage phenotype in an anti-inflammatory direction. Supporting our results, MSCs have
been shown to increase the PD-L1 expression in M2-type macrophages [10].
Strikingly, in Mreg-activated macrophages, the hBMSC secretome increased the expression of
MerTK, which was generally negative in the cells. The different PBMC donors; however, responded
in a different manner. MerTK is a marker of anti-fibrotic M2c macrophages [44], it is important in
the clearance of apoptotic cells [45] and induces SPM production in macrophages [46]. Interestingly,
EVs from cardiosphere-derived cells are able to increase the MerTK expression of macrophages via the
transfer of microRNA-26a [47], which may indicate that the EVs in the hBMSC secretome are mediating
the increased MerTK expression. It has been well established that EVs mediate a large proportion of
the immunomodulatory effects of MSCs [48]. Although we did not examine the effect of EVs alone,
we can hypothesize that observed anti-inflammatory and proresolving effects of hBMSC secretome
were at least in part mediated by the EV fraction.
The secretome of hBMSCs had a larger impact on the phenotype of macrophages than the hBMSC
cell-cell contact. Mainly, the cell-cell contact lowered the HLA-DR expression of Mreg-polarized and,
to a certain extent, Mreg-activated macrophages. HLA-DR is a proinflammatory marker and is involved
in the T-cell activation via antigen presentation. In agreement with our result, human MSCs can
diminish the HLA-DR expression of macrophages and monocytes [49,50] indicating that the hBMSC
cell-cell contact also rendered the macrophage phenotype more anti-inflammatory.
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The PUFA supplementation of hBMSCs prior the coculture with macrophages resulted in a
more pronounced anti-inflammatory phenotype of Mregs. In particular, the secretome of DHA-
hBMSCs increased the CD163 expression and decreased the gene expression of gelatinase MMP-2 in
Mreg-polarized macrophages while control- or AA-hBMSCs had no effect. CD163 is a hemoglobin
scavenger receptor inducing an anti-inflammatory response and its increased expression is one
of the major changes in the macrophage switch to alternatively activated phenotype [51]. On the
other hand, M1 macrophages secrete MMP-2 to induce the degradation of extracellular matrix and
recruitment of inflammatory cells to the site of tissue injury [52]. Previous studies have shown that
MSCs are able to decrease the gene expression of MMP-2 of macrophages in vitro [53] and in vivo [54]
corroborating with our results. The secretome of AA-hBMSCs did not have a significant effect on
the PD-L1 expression in Mreg-polarized macrophages while control and DHA-hBMSCs increased
this expression. This result hints that AA supplementation could lower the immunosuppressive
properties of hBMSCs, because PD-L1 is important in suppressing the T-cell mediated immune
response [42]. Contrastingly, the increase in CD206 expression in Mreg-activated macrophages was the
most prominent with AA-hBMSC secretome.
Previous in vivo studies have reported that EPA-supplemented murine MSCs had superior
therapeutic potential when compared with control MSCs [28,30]. Moreover, DHA-supplemented
murine MSCs increased the survival in an in vivo sepsis model when compared with AA-supplemented
MSCs [29]. In this study, we observed more prominent anti-inflammatory changes in Mregs with
DHA-hBMSCs than with control or AA-hBMSCs; however, the effect was visible in only two phenotype
markers. The lack of a substantial effect of PUFA supplementation to hBMSC immunomodulation in
this in vitro assay may be due to different reasons. Firstly, the PUFA remodeling of hBMSC membranes
takes place relatively quickly, beginning already after 2 h after PUFA supplementation and leading
into prominent remodeling after 24 h [27]. In the current in vitro setting, the medium in the 3-day
macrophage-hBMSC culture contained 10% FBS. Even though this FBS most likely has modified the
cell membranes of hBMSCs and lowered the PUFA content of the membranes, we hypothesized that
the initial modifications in the hBMSC membranes would suffice to induce profound changes already
at the beginning of the coculture. This hypothesis is supported by the studies, where the EPA- and
DHA-supplemented MSCs demonstrated improved therapeutic potential [28–30], even though the cell
membranes of these cells would most likely be remodeled in vivo.
Additionally, our in vitro setting focused on changes in polarized and activated Mregs and
DHA and AA supplementation. Although limited in this experimental setting, PUFA modifications
could still have an impact in hBMSC immunomodulatory properties in other immunological settings.
Moreover, EPA supplementation has been shown to be beneficial for MSC immunomodulation [28,30].
EPA is the precursor to PGE3, which is less proinflammatory than PGE2 [55] and could be one of the
underlying reasons for the pronounced effect of EPA supplementation to MSC immunomodulation.
Thus, the effects of PUFA-modified hBMSCs call for further investigations. If PUFA supplementations
of MSCs prove out to be beneficial, these supplementations represent an easy and safe way to improve
the therapeutic response of MSCs.
The macrophage assays were conducted with primary human PBMCs from individual donors.
We acknowledge the challenges of using primary PBMC-derived macrophages as a model due to their
high plasticity and variability in responding to cytokines and activation. However, by employing
primary human cells, we achieve a more realistic setting than by the use of cell lines, representing
a more physiologically accurate situation and acknowledging the varying responses of the patients
in the clinic. Indeed, the magnitude of the response to different assay conditions and subsequently,
the phenotypes of macrophages derived from individual donors were variable. The hBMSC secretome
induced prominent differences in Mreg-polarized and Mreg-activated macrophages. Some of the
changes in phenotype markers, as in CD206, were clear in all individual donors by the hBMSC
secretome highlighting the significance of this finding. It is also noteworthy that although some of
the effects were small, all of the changes skewed macrophages toward an anti-inflammatory and
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proresolving direction. Moreover, we investigated the effects of hBMSCs derived from three different
donors to multiple buffy coat derived PBMCs, which enhances the robustness of our findings.
To conclude, our results demonstrate that the hBMSC secretome can modify macrophages toward
immunoregulatory and proresolving phenotype, especially by increasing CD206, PD-L1 and MerTK
expression. Moreover, by increasing the CD206 expression, the secretome increased the C. albicans
phagocytosis activity of Mreg-polarized macrophages. According to our hypothesis, hBMSCs skew
macrophages toward a proresolving phenotype that facilitate wound healing and restore homeostasis.
Interestingly, DHA-hBMSCs also increased the expression of CD163 and decreased the gene expression
of MMP-2 in Mreg-polarized macrophages indicating that the DHA modifications have an impact
on the immunomodulatory properties of hBMSCs. These findings highlight the potential of PUFA
supplementations as an easy and safe method to improve the hBMSC therapeutic potential.
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